O11 biomedical GmbH
- Area of Focus:
COPD, hypercapnia
- Competitive advantage:
our product outperforms the gold standard treatment NIV (non-invasive ventilation) by far regarding patient burden and efficacy
- Mode of action:
Breathing via the gut!
- Stage of development:
highly successful in large animals, “First in Patient” planned Q1 2026
- Technology: 4 patents in full ownership, up-scalable in-house production (ISO 13485 expected)
- Raised so far:
9.7M$
- Team:
thrusted and experienced in the fields business, pulmonology, production- and material knowledge, innovation management, IP, biology, QM/QC
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}